OBJECTIVE: To assess the representativeness of drug use treatment samples for measuring HIV seroprevalence among injecting drug users (IDU) in community settings. DESIGN: Seroprevalence was determined in two cross-sectional, convenience samples including an unlinked survey of IDU entrants to all publicly-funded drug-treatment programs and a survey of community-recruited IDU. METHODS: Unconditional logistic regression [odds ratio (OR)] was used to calculate unadjusted and adjusted OR to measure the association between HIV seropositivity and site of recruitment. RESULTS: Between 1988 and 1989, 25% of 870 community-recruited IDU were seropositive, compared with 13% of 671 entrants to drug-treatment programs. This twofold risk of HIV seropositivity among community-recruited IDU remained after adjustment for sample differences in gender, race-ethnicity, and age group (adjusted OR, 2.09; 95% confidence interval, 1.58-2.78). CONCLUSIONS: These results suggest the importance of extending HIV surveillance outside of drug-treatment facilities. Active serologic surveillance may be feasible by coupling recent saliva and fingerstick sampling techniques with existing community outreach education efforts.
OBJECTIVE: To assess the representativeness of drug use treatment samples for measuring HIV seroprevalence among injecting drug users (IDU) in community settings. DESIGN: Seroprevalence was determined in two cross-sectional, convenience samples including an unlinked survey of IDU entrants to all publicly-funded drug-treatment programs and a survey of community-recruited IDU. METHODS: Unconditional logistic regression [odds ratio (OR)] was used to calculate unadjusted and adjusted OR to measure the association between HIV seropositivity and site of recruitment. RESULTS: Between 1988 and 1989, 25% of 870 community-recruited IDU were seropositive, compared with 13% of 671 entrants to drug-treatment programs. This twofold risk of HIV seropositivity among community-recruited IDU remained after adjustment for sample differences in gender, race-ethnicity, and age group (adjusted OR, 2.09; 95% confidence interval, 1.58-2.78). CONCLUSIONS: These results suggest the importance of extending HIV surveillance outside of drug-treatment facilities. Active serologic surveillance may be feasible by coupling recent saliva and fingerstick sampling techniques with existing community outreach education efforts.
Authors: Ricky N Bluthenthal; D Phuong Do; Brian Finch; Alexis Martinez; Brian R Edlin; Alex H Kral Journal: J Urban Health Date: 2007-07-27 Impact factor: 3.671
Authors: F Lamothe; J Bruneau; R Coates; J G Rankin; J Soto; R Arshinoff; M Brabant; J Vincelette; M Fauvel Journal: CMAJ Date: 1993-10-01 Impact factor: 8.262
Authors: Tiffany Zellner; Jennie Trotter; Shelia Lenoir; Kelvin Walston; L'dia Men-Na'a; Tabia Henry-Akintobi; Assia Miller Journal: Int J Environ Res Public Health Date: 2015-12-22 Impact factor: 3.390